Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
542 results about "Anion-exchange chromatography" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Anion-exchange chromatography is a process that separates substances based on their charges using an ion-exchange resin containing positively charged groups, such as diethyl-aminoethyl groups (DEAE). In solution, the resin is coated with positively charged counter-ions (cations). Anion exchange resins will bind to negatively charged molecules, displacing the counter-ion. Anion exchange chromatography is commonly used to purify proteins, amino acids, sugars/carbohydrates and other acidic substances with a negative charge at higher pH levels. The tightness of the binding between the substance and the resin is based on the strength of the negative charge of the substance.
Process for the preparation of a desired erythropoietin glyco-isoform profile
InactiveUS20050153879A1High and uniform product specificityImprove product qualityPeptide/protein ingredientsComponent separationFiltrationRed blood cell
The present invention provides a process for the production of erythropoietin (EPO) with high purity and with a desired profile of EPO glycol-isoforms by using a combination of specific chromatographic steps in such a manner that the starting EPO glycol-isoform profile is changed or modified. The applied chromatographic steps includes at least (a) dye affinity chromatography, and (b) hydrophobic chromatography and / or (c) anion-exchange chromatography. In a preferred embodiment, the process further includes (d) gel filtration chromatography. The present invention also provides a process for the determination of erythropoietin (EPO) glycol-isoform profile in an EPO containing composition.
Owner:SVETINA MONICA +4
Method for preparing human immunoglobulin concentrates for therapeutic use
InactiveUS7186410B2Simple processHighly compatibleAntibacterial agentsSerum immunoglobulinsAnion-exchange chromatographyBlood plasma
The invention concerns a method for preparing human immunoglobulin concentrates for therapeutic use, from plasma or a plasma fraction. The method comprises pre-purification and a single anion-exchange chromatography carried out at alkaline pH, thereby enabling the immunoglobulins to be retained on the chromatographic support and fractionated. The method enables to obtain IgG, IgA and IgM concentrates.
Owner:LABE FR DU FRACTIONNEMENT & DES BIOTECH SA
Separation of polypeptide monomers
InactiveUS20020010319A1Easy to separateInexpensiveComponent separationOther chemical processesAnion-exchange chromatographyAnion Exchange Proteins
A method is disclosed for separating a polypeptide monomer from a mixture comprising dimers and / or multimers. The method comprises applying the mixture to either a cation-exchange chromatography resin or an anion-exchange chromatography resin and eluting the mixture at a gradient of about 0-1 M of an elution salt, wherein the monomer is separated from the dimers and / or multimers present in the mixture.
Owner:GENENTECH INC
Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
ActiveUS20090050566A1Improve bindingGood removal effectCation exchanger materialsIon-exchanger regenerationPurification methodsSorbent
Media and devices, such as anion exchangers including such media, wherein the media is a membrane having a surface coated with a polymer such as a polyallylamine. The resulting membrane offers stronger binding of protein impurities and superior removal of host cell proteins from biological samples than conventional ligands based on quaternary ammonium salts, including trimethylammonium ligands. Also described is a chromatography scheme and method for purifying monoclonal antibodies, wherein the anion exchange sorber is placed downstream of an affinity column (such as Protein A or Protein G affinity column) and optionally one or more polishing devices such as cationic exchange columns. Little or no dilution of the cation exchanger pool (or affinity column exchange pool where no cation exchanger is used) is necessary to lower the conductivity of the sample. The sorber functions well to strongly bind host cell proteins and other impurities in biological samples even at high conductivities and pH.
Owner:MILLIPORE CORP
Bone health compositions derived from milk
InactiveUS20040052860A1Reducing net bone lossMetabolism disorderProtein composition from milkHydrolysatePhysiology
The invention relates to bone health compositions comprising an acidic protein fraction of milk, to a method of producing said bone health composition, to methods of treatment comprising said bone health compositions and to medicinal uses of said bone health compositions. One broad aspect of the invention provides a bone health composition comprising an acidic protein fraction derived from milk, from a component of milk, from whey, from hydrolysates thereof, or from a combination thereof, or from a combination thereof wherein the composition does not comprise caseinoglycomacropeptide (CGMP). Another broad aspect provides a method of manufacturing the composition of the invention using anion exchange chromatography.
Owner:NEW ZEALAND DAIRY BOARD
Process for the production of nucleotide sugars
InactiveUS20100174059A1Reduce formationHigh puritySugar derivativesSugar derivatives preparationFiltrationPolyethylene glycol
The current invention provides methods (e.g., large-scale processes) for the production of nucleotide sugars, which are modified with a polymeric modifying group, such as poly(alkylene oxide) moieties (e.g., poly(ethylene glycol) or poly(propylene glycol)) moieties. A typical process of the invention includes anion exchange chromatography followed by an ultrafiltration procedure, such as tangential flow filtration. The process of the invention provides modified nucleotide sugars in unexpectedly high purity and high overall yields.
Owner:RATIOPHARM GMBH
Methods of Purifying Recombinant Adamts13 and Other Proteins and Compositions Thereof
ActiveUS20110081700A1Reduce formationExtension of timeInactivation/attenuationBiomass after-treatmentHydroxylapatiteAnion-exchange chromatography
Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange / hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration / diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.
Owner:TAKEDA PHARMA CO LTD
Chromatographic method for high yield purification and viral inactivation of antibodies
InactiveUS6955917B2Minimizes post virus treatment manipulationYield maximizationPeptide/protein ingredientsSerum immunoglobulinsLipid formationLow ionic strength
An improved process for the purification of antibodies from human plasma or other sources is disclosed. The process involves suspension of the antibodies at pH 3.8 to 4.5 followed by addition of caprylic acid and a pH shift to pH 5.0 to 5.2. A precipitate of contaminating proteins, lipids and caprylate forms and is removed, while the majority of the antibodies remain in solution. Sodium caprylate is again added to a final concentration of not less than about 15 mM. This solution is incubated for 1 hour at 25° C. to effect viral inactivation. A precipitate (mainly caprylate) is removed and the clear solution is diluted with purified water to reduce ionic strength. Anion exchange chromatography using two different resins is utilized to obtain an exceptionally pure IgG with subclass distribution similar to the starting distribution. The method maximizes yield and produces a gamma globulin with greater than 99% purity. The resin columns used to obtain a high yield of IgG retain IgM and IgA. IgA and IgM may be eluted from these resins in high yield and purity.
Owner:BAYER HEALTHCARE LLC
Production of organic and inorganic selenium compounds by lactic acid bacteria
InactiveUS20070077238A1Improve feed conversionEnhanced Glutathione Peroxidase （GPx） activityBiocideBacteriaHigh concentrationAnion-exchange chromatography
A novel strain of lactic acid bacteria was found to be heat resistant and able to grow in a sulfur-limiting medium (SLM) containing a high concentration of sodium selenite. The microorganism is a non-spore forming and Gram-positive coccus, which is identified with >90% confidence using the API biochemical and sugar fermentation tests, ribotyoing and 16S rRNA sequencing as Pediococcus pentosaceus SP80. In the current study, P. pentosaceus SP80 grown on SLM containing 250 ppm sodium selenite produced both organic and inorganic forms of selenium. These selenium compounds can be separated using an anion exchange chromatography technique. The concentrations of selenium detected in the organic and inorganic fractions were 4.34 and 21.7 ppm, respectively. Selenium-enriched bacteria are useful as a source of selenium for supplementing the diets of animals and humans. Animals fed efficacious amounts of the selenium-enriched bacteria show improved feed conversion rates and higher levels of glutathione peroxidase (GPx) activity in heart, kidney and liver tissues indicating an increased absorption and retention of selenium over control diets.
Owner:KEMIN IND INC
Purification of human monoclonal antibody and human polyclonal antibody
InactiveUS20060257972A1Serum immunoglobulinsImmunoglobulins against animals/humansAntiendomysial antibodiesAnion-exchange chromatography
This invention provides a method for separating and purifying human monoclonal antibodies and human polyclonal antibodies from an antibody-containing mixture where such antibodies are primarily used for therapeutic applications and are occasionally used for diagnostic and reagent applications. This method comprises at least the following steps of: (1) purification via anion exchange chromatography; (2) purification via cation exchange chromatography following step (1); and separation of human antibodies from artiodactyl antibodies from a mixture that contains human antibodies and artiodactyl antibodies via protein A affinity chromatography that employs pH gradient elution.
Owner:KIRIN BREWERY CO LTD
Method for purifying anti-HER2 or/and anti-HER3 antibody proteins
ActiveCN102492040ASpeed up filteringReduce manufacturing costImmunoglobulins against cell receptors/antigens/surface-determinantsPeptide preparation methodsVirus inactivationPurification methods
The invention belongs to the biochemistry technical field, concretely relates to a method for purifying anti-HER2 or / and anti-HER3 antibody proteins. The method of the invention comprises the following the steps: clarifying a broth, carrying out affinity chromatography, carrying out inactivation on virus by acidic pH value, carrying out cation exchange chromatography, carrying out anion exchange chromatography; and filtering virus; wherein, the step of virus inactivation by acidic pH value and the step of virus filtration can be inserted at any position of the step after the affinity chromatography. The method of the invention comprises the following advantages that: 1) the chromatography step can be reduced to three steps, thereby the production efficiency can be enhanced and the production cost can be minimized. 2) the step of virus filtration is added, thereby the security can be raised.
Owner:GENOR BIOPHARMA +1
Method of preparing alpha-1 proteinase inhibitor
InactiveUS20110237781A1High yieldHigh purityDepsipeptidesPeptide preparation methodsAnion-exchange chromatographyBlood plasma
Purification of α-1 proteinase inhibitor (α-1 PI) from solutions comprising α-1 PI is accomplished using hydrophobic interaction chromatography (HIC). In some embodiments, purification of α-1 PI is accomplished by precipitation of contaminating proteins from a starting solution comprising α-1 PI, such as human plasma, followed by anion exchange resin chromatography prior to HIC. Further purification may be accomplished by an optional cation exchange chromatography subsequent to anion exchange chromatography but prior to HIC. Some embodiments of the invention also include virus removal and / or inactivation by methods such as nano filtration and such as contact with a non-ionic detergent. The methods of the present invention result in greater yield, purity, and pathogenic clearance of plasma fractions than known methods.
Owner:GRIFOLS THERAPEUTICS INC
Intravenous injection of cytomegalovirus human immunoglobulin and its preparation method
ActiveCN102286099ASteps to reduce precipitationKeep aliveImmunoglobulins against virusesAntiviralsEthanol precipitationAnion-exchange chromatography
The invention discloses a human cytomegalovirus immunoglobulin for intravenous injection and a preparation method thereof, and aims to improve the purity, yield and safety of the product. In the invention, the specific activity of the human cytomegalovirus immunoglobulin for intravenous injection is not less than 2.5 PEI-U / mg, the anti-CMV titer is not less than 100 PEI-U / ml, the purity is greater than 98.2%, and the protein content is 51-55 mg / ml. Caprylic acid precipitation and anion exchange chromatography are used instead of the partial ethanol precipitation step in the traditional low-temperature ethanol method, thereby keeping IgG in the supernate all the time so as to keep the IgG activity; and processes of caprylic acid virus inactivation and nano film virus removal are used, thereby effectively ensuring the safety of the product. Researches show that the preparation method disclosed by the invention improves the purity, yield and safety of the product, saves the energy and reduces the production cost.
Owner:SHENZHEN WEIGUANG BIOLOGICAL PROD
Method for preparing antibody-maytansine alkaloid medicine conjugate
ActiveCN103254311AReduce hidden dangersImprove efficiencyImmunoglobulins against cell receptors/antigens/surface-determinantsPeptide preparation methodsAnion-exchange chromatographyAlkaloid
The invention relates to a method for preparing antibody-maytansine alkaloid medicine conjugate. The method comprises the following steps of replacing the antibody into a reaction buffer solution; dissolving a dual-function bridging agent-maytansine alkaloid with an organic solvent so as to prepare the mother liquor of maytansine alkaloid medicine; mixing the replaced antibody with the mother liquor of maytansine alkaloid medicine for coupled reaction for 1-4 hours at 20-30 DEG C; and carrying out anion exchange chromatography on the reaction liquid, conducting Sephadex TMG25 desalination chromatographic column purification on collected flow liquid, and collecting a first peak sample as the prepared antibody-maytansine alkaloid medicine conjugate. The prepared antibody-maytansine alkaloid medicine conjugate is proper in coupling rate, high in purity and low in endotoxin content.
Owner:QILU PHARMA CO LTD
Detection of nucleic acid heteroduplex molecules by anion-exchange chromatography
InactiveUS6969587B2Easy to useGuaranteed uptimeImmobilised enzymesBacteriaOrganic solventAnion-exchange chromatography
The present invention describes a method for separating or partially separating heteroduplex and homoduplex DNA molecules in a mixture. In the method, the mixture is applied to an anion-exchange chromatography medium. The heteroduplex and homoduplex molecules are eluted with a mobile phase containing an eluting salt, including an anion and a cation, a buffer, and preferably including an organic solvent. The eluting is carried out under conditions effective to at least partially denature the heteroduplexes (e.g., thermal or chemical denaturing) resulting in the separation of the heteroduplexes from the homoduplexes. The method has many applications including, but not limited to, detecting mutations and comparative DNA sequencing.
Owner:ADS BIOTEC INC
Method for purifying recombinant human serum albumin protein and application thereof
The present invention relates to a method for purifying recombinant human serum albumin (rHSA) protein. The method comprises the following steps: fermented liquid containing rHSA is processed by a ceramic membrane, supernatant liquid is orderly purified by high salt cation exchange chromatography, hydrophobic layer exchange chromatography and weak anion exchange chromatography, and purified rHSA is obtained. The present invention is characterized in that solution processed by high salt cation exchange chromatography is processed by borate and then filtered by hollow fibers. The rHSA obtained can be used for producing vaccines for humans against viruses with a cell culture method, particularly rabies vaccines.
Owner:NCPC NEW DRUG RES & DEV
Method for preparing bonito stick protein hydrolysate with effect of reducing uric acid
ActiveCN104337836AGood effectHigh purityHydrolysed protein ingredientsSkeletal disorderSerum uric acidArginine
The invention relates to a method for preparing bonito stick protein hydrolysate with an effect of reducing uric acid. The method comprises the following main steps of raw material heat treatment, restriction digestion, membrane separation-anion exchange chromatography-gel filtration chromatography separation, concentration and spray drying so as to obtain the bonito stick protein hydrolysate with an effect of reducing uric acid. The amino acid analysis indicates that the zymolyte peptide fragment primary amino acid sequence contains four amino acids, namely histidine, arginine, lysine and threonine, the total mass content of the four amino acids is 70 percent of the total amino acid content of zymolyte. MALDI-TOF-MS mass spectrum determines that the molecular weight of the main peptide effective ingredient is less than 700Da. In-vitro uric acid reduction experiments prove that the bonito stick protein hydrolysate has a remarkable effect of inhibiting generation of uric acid, and has an inhibition rate over 50 percent; an oteracil potassium molded hyperuricemic rat animal model indicates that the bonito stick protein hydrolysate can be used for remarkably reducing the level of serum uric acid and serum creatinine of rats, and shows a relatively good kidney protecting effect.
Owner:SOUTH CHINA UNIV OF TECH
High Purity Lipopeptides
The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of Streptomyces roseosporus. The invention also discloses high pressure liquid chromatography methods for analysis of daptomycin purity. The invention also discloses lipopeptide micelles and methods of making the micelles. The invention also discloses methods of using lipopeptide micelles for purifying lipopeptide antibiotics, such as daptomycin. The invention also discloses using lipopeptide micelles therapeutically.
Owner:CUBIST PHARMA INC
Production method of Sublancin antibacterial peptide
InactiveCN102851339AIncrease productionHigh purityMicroorganism based processesDepsipeptidesCentrifugationUltrafiltration
The invention provides a preparation method of Sublancin antibacterial peptide, which comprises the following steps: (1) inoculating bacillus subtilis into a medium for fermentation, filtering the fermentation liquor; (2) orderly performing centrifugation, cation exchange chromatography, hydrophobic chromatography, size exclusion chromatography, and anion exchange chromatography of the fermentation liquor in step (1), finally performing ultrafiltration concentration and drying to obtain the Sublancin antibacterial peptide. The method of the invention is low in cost, increased in production efficiency, and high in product purity; the prepared Sublancin antibacterial peptide has purity of up to more than 99%; the process is simple, and easy to popularize and apply, and can realize large-scale production.
Owner:中农颖泰林州生物科园有限公司
Process for the purification of fc-fusion proteins
InactiveUS20100267932A1Peptide preparation methodsFermentationAnion-exchange chromatographyAnion Exchange Proteins
The invention relates to a process for the purification of an Fc-fusion protein having a pI between 6.9 and 9.5 comprising protein A or G affinity chromatography, cation exchange chromatography, anion exchange chromatography and hydroxyapatite chromatography.
Owner:EON DUVAL ALEX +1
Leech extract and preparation method and use thereof
InactiveCN101332211AHigh purityHigh activityNervous disorderBlood disorderPharmacy technologyUltrafiltration
The present invention discloses a preparation method of bloodsucker extract, in which the bloodsucker is added with water and homogenized, and then the bloodsucker extract is obtained by controllable enzymolysis, organic solvent precipitation, ultrafiltration and anion-exchange chromatography. The bloodsucker extract can be adopted to prepare a medicine with anticoagulation, thrombolytic ability, inhibition on platelet aggregation and neuroprotection effect. The present invention, according to the modern technological requirements of Chinese medicine, adopts the technology of controllable enzymolysis for extracting the peptide component, the separating technology of ultrafiltration and gel chromatography for purification further, and the biological pharmacy technology, thus obtaining the extract with higher pureness and stronger activity than the traditional bloodsucker extract. The method breaks through the bottleneck of the traditional animal medicine in extraction and separation, solves the problem of the traditional animal medicine that the amount of raw powder is large and the taste is fishy, improves the activity and quality controllability of the animal medicine extract further and greatly improves the utilization rate of medicinal materials.
Owner:SHANDONG UNIV
Method for separating and purifying immunoglobulin A, immunoglobulin G and lactoferrin from bovine colostrum in industrializing way
ActiveCN101724013AReduce pollutionIncrease productivityTransferrinsMilk immunoglobulinsAnion-exchange chromatographyLactoferrin
The invention provides a method for separating and purifying immunoglobulin A, immunoglobulin G and lactoferrin from bovine colostrum in an industrializing way, which comprises the following steps of: (1) degreasing the bovine colostrum and separating casein to prepare whey; (2) after micro-filtering the whey for degerming, carrying out cation exchange chromatography to obtain a first fast flow liquid, eluting a chromatographic column to obtain eluent, ultra-filtering, concentrating and desalting the eluent by using a first ceramic membrane, and freezing and drying to obtain the lactoferrin; (3) carrying out anion exchange chromatography on the first fast flow liquid to obtain a second fast flow liquid, eluting the chromatographic column to obtain eluent, ultra-filtering, concentrating and desalting the eluent by using a second ceramic membrane, and freezing and drying to obtain the immunoglobulin A; and (4) ultra-filtering, concentrating and desalting the second fast flow liquid by using a third ceramic membrane, and obtaining the immunoglobulin G by using low-temperature spray drying. By utilizing the method, the immunoglobulin A, the immunoglobulin G and the lactoferrin can be separated and purified from the bovine colostrumin efficiently and continuously in the industrializing way.
Owner:HEILONGJIANG KANPURE BIOTECH
Separation and purification method of bacillus amyloliquefaciens antimicrobial proteins
InactiveCN102153618AHigh purityHigh antibacterial activityPeptide preparation methodsPurification methodsAntibiotic resistance
The invention discloses a separation and purification method of bacillus amyloliquefaciens antimicrobial proteins, relating to a separation and purification method of bacillus antimicrobial proteins. The method solves the problems that the existing separation and purification method of proteins can not acquire bacillus amyloliquefaciens TF28 antimicrobial proteins with high purity, generates various impurity proteins and is low in the yield of antimicrobial proteins. The method includes the following steps: I. obtaining the crude extract of antimicrobial proteins; II. obtaining protein concentrate by anion exchange chromatography; and III. performing gel filtration chromatography through a molecular sieve to obtain bacillus amyloliquefaciens antimicrobial proteins. The separation and purification method is used for the separation and purification of bacillus amyloliquefaciens antimicrobial proteins.
Owner:INST OF MICROBIOLOGY HEILONGJIANG ACADEMY OF SCI
Purification of recommbined human urokinase zymogen
ActiveCN1680550AEasy to fillLarge amount of processingPeptide preparation methodsPeptidasesZymogenUrokinase Plasminogen Activator
The invention is about a method to purify the recombined human urokinase by the chromatography. The invention relates to recovery the gene engineering production from the mammal cell culture using the Streamline-SP, Sephacryl S-200, Sepharose Fast Flow and DEAE-Sepharose Fast Flow method. The recombined human urokinase can meet the SFDA standard and the percent recovery is above 70%, the purity is above 99% by using the method.
Owner:TASLY BIOPHARMACEUTICALS CO LTD
Antibacterial lipopeptide of endophytic Bacillus subtilis and separation and purification method
InactiveCN101724014ABroad antibacterial spectrumImprove thermal stabilityMicroorganism based processesFungicidesPesticide residueAntifungal drug
Owner:JIANGSU ACAD OF AGRI SCI
Process for The Manufacture of Virus Safe Immunoglobulin
InactiveUS20070244305A1Eliminate the problemEfficient precipitationSerum immunoglobulinsPeptide preparation methodsProtein aggregationAnion-exchange chromatography
Process for preparing a purified immunoglobulin preparation. The process comprises the steps of subjecting a crude immunoglobulin solution to caprylic acid treatment, removing protein aggregates and viruses from the immunoglobulin solution, subjecting the immunoglobulin solution to anion exchange chromatography in order to purify the immunoglobulin, filtering the immunoglobulin solution thus obtained on a virus-removal filter to produce an eluate containing immunoglobulin, and recovering the immunoglobulin. By combining caprylic acid treatment and precipitation with a protein precipitant the level of aggregated proteins and viruses is effectively reduced and a truly virus safe preparation is provided after filtration.
Owner:SUOMEN PUNAINEN RISTI VERIPALVELU
Method for extracting rabies virus
InactiveCN101270350AImprove removal efficiencyGood removal effectSsRNA viruses negative-senseMicroorganism based processesHollow fibreFiber
The invention provides a method for extracting rabies virus, and is to solve the defects that great discrepancy of quality indices of different batches occurs; removal of remaining DNA becomes difficult; the protein content of the remaining host is too high; and great side effects appear clinically when the single method of molecular sieve gel chromatography is adopted for extracting rabies virus vaccine. The essential of the invention is that a hollow fiber ultrafiltration column or ultrafiltration membrane with the molecular weight cut-off of 750KD or 500KD is used to condense and partially purify harvested liquid of virus; anion exchange chromatography or molecular sieve gel chromatography is adopted to separate and purify samples; molecular sieve gel chromatography or anion exchange chromatography is adopted to separate and purify samples got in step (2). The method for extracting rabies virus has the characteristics of great productive capacity, high product quality, excellent batch stability, being remarkably effective in removal of remaining DNA and HCP, and reducing the potential safety hazard of vaccine.
Owner:LIAONING YISHENG BIOLOGY PHARMACY
Method for purifying plasmid DNA
InactiveUS20070213289A1Yield maximizationProtozoaGenetic therapy composition manufactureLysisFiltration
This invention provides a process for the continuous alkaline lysis of a bacterial suspension in order to harvest pDNA. It further provides for optional additional purification steps, including lysate filtration, anion exchange chromatography, triplex affinity chromatogragphy, and hydrophobic interaction chromatography. These optional purification steps can be combined with the continuous lysis in order to produce a highly purified pDNA product substantially free of gDNA, RNA, protein, endotoxin, and other contaminants.
Owner:AVENTIS PHARMA SA (US)
Sophora fungus mycoplasma extract identification and detection method
ActiveCN102621260AControl contentRaise quality standardsComponent separationMonosaccharide compositionAnion-exchange chromatography
The invention relates to a sophora fungus mycoplasma extract identification and detection method. The identification method is characterized in that an anion exchange chromatography method is used for establishing chromatographic fingerprint composed by monosaccharide of proteoglycan protein in the sophora fungus mycoplasma extract, and the quality is controlled by comparing the similarity of a sample fingerprint spectrum and a fingerprint spectrum of a standard extract. The detection method is characterized in that the anion exchange chromatography method is used for detecting the monosaccharide composition and content of proteoglycan protein of the sophora fungus mycoplasma extract, thereby the content limit can be made. The fingerprint spectrum of the anion exchange chromatography method combines the content determination method to realize the effective control of quality of the sophora fungus mycoplasma extract and the relative products as well as distinguish with other products. The method of the invention has the advantages of rapidity, convenience and strong specificity.
Owner:QIDONG GAITIANLI MEDICINES
Method for preparing human immunoglobulin
ActiveCN102532307ASmall volumeReduce manufacturing costSerum immunoglobulinsPeptide preparation methodsOctanoic AcidsVirus inactivation
The invention provides a method for preparing human immunoglobulin. The method comprises the following steps of: dissolving Cohn components I, II and III and Cohn components II and III, precipitating by using octanoic acid, performing anion-exchange chromatography for the first time, precipitating IgM, performing anion-exchange chromatography for the second time, performing ultrafiltration or dialyzing, preparing, inactivating virus and the like to obtain the high-purity human immunoglobulin. The invention also provides the human immunoglobulin prepared by the method and a medicinal composition. The method for preparing the human immunoglobulin is simple, and low in cost and has good industrial application prospect.
Owner:CHENGDU RONGSHENG PHARMA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com